Drug profile · INN
autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence
STRIMVELIS
autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence (STRIMVELIS) is a ada exogenous gene.
Drug details — autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- —
- Patents
- 1
- Programs
- 0
- Data quality
- 0.83
Quick answer
autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence (STRIMVELIS) is a ada exogenous gene.
Key facts
Mechanism of action
ADA exogenous gene
Primary target: ADA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence?
autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence (STRIMVELIS) is a ada exogenous gene.
What is the brand name for autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence?
STRIMVELIS is a marketed brand name for autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence. Check FDA Drugs@FDA for the current US label holder and prescribing information.